Lamivudine prophylaxis prevents hepatitis b reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non–hodgkin's B cell lymphoma. (15th February 2015) - Viganò, M.; Grossi, G.; Borsotti, E.; Cappelletti, M.; Goldaniga, M.; Farina, L.; Rumi, M.; Corradini, P.; Baldini, L.; Colombo, M.; Lampertico, P.